Advertisement
Advertisement
ENTA
Enanta Pharmaceuticals, Inc
13.53
USDSponsored
+0.56
+4.30%
Feb 06, 15:59 UTC -5
Closed
After-Market
13.54
+0.01
+0.05%
ENTA Earnings Reports
Positive Surprise Ratio
ENTA beat 25 of 39 last estimates.
64%
Next Report
Tomorrow
Date of Next Report
Feb 09, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.46M
/-$0.82
Implied change from Q4 25 (Revenue/ EPS)
+8.84%
/-5.75%
Implied change from Q1 25 (Revenue/ EPS)
-2.93%
/-21.90%
Enanta Pharmaceuticals, Inc earnings per share and revenue
On Nov 17, 2025, ENTA reported earnings of -0.87 USD per share (EPS) for Q4 25, beating the estimate of -1.04 USD, resulting in a 16.46% surprise. Revenue reached 15.13 million, compared to an expected 16.28 million, with a -7.07% difference. The market reacted with a -3.59% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 16.46 million USD, implying an decrease of -5.75% EPS, and increase of 8.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Enanta Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Enanta Pharmaceuticals, Inc reported EPS of -$0.87, beating estimates by 16.46%, and revenue of $15.13M, -7.07% below expectations.
How did the market react to Enanta Pharmaceuticals, Inc's Q4 2025 earnings?
The stock price moved down -3.59%, changed from $12.82 before the earnings release to $12.36 the day after.
When is Enanta Pharmaceuticals, Inc expected to report next?
The next earning report is scheduled for Feb 09, 2026.
What are the forecasts for Enanta Pharmaceuticals, Inc's next earnings report?
Based on 6
analysts, Enanta Pharmaceuticals, Inc is expected to report EPS of -$0.82 and revenue of $16.46M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement